IPP Bureau
INDIA-EU FTA unlocks access to $572.3 billion EU pharmaceuticals & medical devices market
By IPP Bureau - January 29, 2026
Growth across inorganic & organic chemicals, fertilisers, pharmaceuticals, cosmetics, soaps and detergents
Lubrizol showcases India manufacturing expansion at WHX Dubai
By IPP Bureau - January 29, 2026
The Chennai facility will manufacture high-quality medical tubing for neurovascular and cardiovascular applications, including balloon catheters and other minimally invasive devices
Will Forte joins Teva Pharmaceuticals to shine spotlight on Huntington’s disease
By IPP Bureau - January 29, 2026
HD causes cognitive, behavioral, and physical challenges, including involuntary movements known as HD chorea, which can disrupt daily life
Roche’s investigational obesity drug CT-388 delivers dramatic weight loss in Phase II trial
By IPP Bureau - January 29, 2026
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience
By IPP Bureau - January 29, 2026
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
Bausch Health’s RED-C phase 3 trials fall short, company committed to liver disease research
By IPP Bureau - January 29, 2026
The trials, which enrolled over 1,000 patients across 398 sites in 17 countries, showed that the drug was safe and well-tolerated—but ultimately failed to deliver the hoped-for clinical results
Insilico Medicine’s AI-designed Parkinson’s drug cleared for human trials by FDA
By IPP Bureau - January 29, 2026
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
CitiusTech & Ventra Health unveil AI-powered revenue game-changer
By IPP Bureau - January 29, 2026
The platform uses cutting-edge AI and automation to tackle the entire revenue cycle
Venus Remedies bags second PLI disbursement for FY25, nears full-year incentive
By IPP Bureau - January 29, 2026
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
Eyestem moves closer to blindness breakthrough with phase 2 trial green light
By IPP Bureau - January 29, 2026
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
Cupid gets certification for HIV & Hepatitis B test kits, paving way for global expansion
By IPP Bureau - January 29, 2026
The newly certified kits are designed for early detection and large-scale screening programs
Sanofi’s Amlitelimab delivers in Phase 3 trials, heads for global filings
By IPP Bureau - January 28, 2026
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
Trelegy Ellipta gets green light in China for adults with uncontrolled asthma
By IPP Bureau - January 28, 2026
The approval expands the drug’s existing COPD indication, making it the only single-inhaler triple therapy (SITT) available for both respiratory conditions in China
Hongene Biotech bags Gates Foundation grant to boost global mRNA vaccine access
By IPP Bureau - January 28, 2026
Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
Eastman & Kolmar Korea join forces to deliver biodegradable beauty breakthroughs
By IPP Bureau - January 28, 2026
The collaboration will center on expanding access to Eastman’s Esmeri technology
